Literature DB >> 15851586

Prognostic implications of warfarin cessation after major trauma: a population-based cohort analysis.

Daniel G Hackam1, Alexander Kopp, Donald A Redelmeier.   

Abstract

BACKGROUND: Warfarin therapy is often withheld from elderly patients who fall or otherwise experience injury because of concerns regarding the long-term risk of hemorrhage in these individuals. We studied whether stopping warfarin after trauma is associated with a higher risk of subsequent adverse cardiovascular events. METHODS AND
RESULTS: We conducted a retrospective, population-based, cohort study using linked administrative databases in the province of Ontario, Canada for the years 1992 to 2001. A total of 8450 elderly patients (age >65 years) who survived an incident of major trauma and were receiving warfarin before injury were followed up for a mean of 3.3 years. During the 6-month interval after trauma, 1827 (22%) patients discontinued warfarin, whereas 6623 (78%) patients continued warfarin. Warfarin cessation was not associated with an increased risk of subsequent stroke (hazard ratio [HR] 0.99, 95% CI 0.82 to 1.21) or myocardial infarction (HR 0.94, 95% CI 0.74 to 1.20) but was associated with a lower risk of major hemorrhage (HR 0.69, 95% CI 0.54 to 0.88) and a higher risk of venous thromboembolism (HR 1.59, 95% CI 1.07 to 2.36). Adjustment for baseline demographics, stroke risk factors, other comorbidities, and characteristics of the trauma did not materially change these findings. On-treatment analyses yielded similar results.
CONCLUSIONS: Cessation of warfarin in elderly patients after major trauma was not associated with an increased risk of arterial thrombotic events but was associated with a significantly increased risk of venous thromboembolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15851586     DOI: 10.1161/01.CIR.0000163548.38396.E7

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy.

Authors:  Andrea Rubboli; Cecilia Becattini; Freek Wa Verheugt
Journal:  World J Cardiol       Date:  2011-11-26

2.  A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.

Authors:  E Stepien; A Branicka; M Ciesla-Dul; A Undas
Journal:  J Appl Genet       Date:  2009       Impact factor: 3.240

3.  Vitamin K, fresh frozen plasma, and platelet transfusion used to arrest progression of intracranial hemorrhage after traumatic brain injury in a patient taking anticoagulant and antiplatelet agents.

Authors:  Joe Yoshizawa; Jun Namiki; Yusho Nishida; Yasushi Kaneko; Shingo Hori
Journal:  Acute Med Surg       Date:  2016-04-26

4.  Thrombus in a coronary artery aneurysm shortly after warfarin withdrawal.

Authors:  Sophie Alloul; Nagib Dahdah; Joaquim Miró
Journal:  Pediatr Cardiol       Date:  2008-07-30       Impact factor: 1.655

5.  Impact of anticoagulation and antiplatelet drugs on surgery rates and mortality in trauma patients.

Authors:  Felix M Bläsius; Markus Laubach; Hagen Andruszkow; Cavan Lübke; Philipp Lichte; Rolf Lefering; Frank Hildebrand; Klemens Horst
Journal:  Sci Rep       Date:  2021-07-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.